Pfizer Ltd. (PFIZER) — Tipsheet https://tipsheet.markets/company/pfizer/ Every Tipsheet Editorial note covering Pfizer Ltd. (PFIZER), newest first. Grounded in BSE/NSE primary-source filings. en-in Mon, 27 Jul 2026 14:33:15 GMT Pfizer loses CFO Amit Agarwal; no successor named https://tipsheet.markets/pfizer-pfizer-loses-cfo-amit-agarwal-no-successor-named-128004/ https://tipsheet.markets/pfizer-pfizer-loses-cfo-amit-agarwal-no-successor-named-128004/ Mon, 27 Jul 2026 16:34:47 GMT Amit Agarwal resigns to pursue external opportunity, stays until Oct 8, 2026. No successor or disagreement disclosed, adding uncertainty for a mid-cap pharma with declining profits. Amit Agarwal resigns to pursue external opportunity, stays until Oct 8, 2026. No successor or disagreement disclosed, adding uncertainty for a mid-cap pharma with declining profits.

What’s new

  • CFO Amit Agarwal resigns, citing external opportunity.
  • He serves until Oct 8, 2026, a notice period of over two months.
  • No successor announced; no disagreements cited.

Why it matters

A CFO departure without an immediate successor introduces uncertainty in financial stewardship. For a mid-cap pharma with trailing PAT down 39.6% and ongoing restructuring, the leadership gap adds risk until clarity emerges.

What we’re watching

  • Whether a successor is named before October 8, 2026.
  • Any impact on portfolio restructuring or product launches.
  • Stock reaction to the unexpected leadership change.

The full read

Pfizer Ltd has lost its CFO. Amit Agarwal, who also sat on the board and key committees, resigned to take another job. He stays until October 8, 2026 — a notice period of over two months. The company named no successor and cited no dispute. For a ₹20,407 cr mid-cap pharma with trailing PAT down 39.6% and ongoing restructuring, even a smooth transition feels like a gap until filled. The open question is who steps in next.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial